Antibody–Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions

Antibody–drug conjugates (ADCs) are a rapidly evolving class of oncology therapeutics that enable precise delivery of potent cytotoxic agents to tumor cells while minimizing systemic toxicity. While HER2-targeted ADCs such as trastuzumab deruxtecan (T-DXd) in HER2-mutant, Datopotamab deruxtecan (Dat...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ahmed Ismail, Aakash Desai, George R. Simon, Yanis Boumber
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-05-01
Edice:	Biomolecules
Témata:	non-small cell lung cancer (NSCLC) antibody–drug conjugates (ADCs) TROP2 HER3 MET CEACAM5
On-line přístup:	https://www.mdpi.com/2218-273X/16/5/677
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!